Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT3 | O60678 | 1/20 | 0.71 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.71 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.71 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.71 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.53 |
| ▸ | CCR3 | P51677 | 1/20 | 0.51 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.51 |
| ▸ | GMNN | O75496 | 1/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.51 |
| ▸ | THPO | P40225 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | BLM | P54132 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10712825 | 0.98 | PRMT3 (0.69) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| Hydrochloric Acid SCHEMBL10714052 | 0.98 | PRMT3 (0.69) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL6217711 | 0.91 | PRMT3 (0.59) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL24076352 | 0.84 | PRMT3 (0.63) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL6164511 | 0.84 | GRIN2B (0.54) | SLC6A2SLC6A4SLC6A3OPRM1CCR3 | |
| SCHEMBL543919 | 0.83 | PRMT6 (1.00) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| Hydrochloric Acid SCHEMBL7296894 | 0.83 | OPRM1 (0.58) | SLC6A2SLC6A4SLC6A3OPRM1GRIN2B | |
| Hydrochloric Acid SCHEMBL9869979 | 0.82 | PRMT6 (0.97) | PRMT3CARM1PRMT6PRMT1PRMT8 | |
| SCHEMBL9396839 | 0.81 | CCR3 (0.57) | OPRM1CCR3GRIN2B | |
| SCHEMBL11518718 | 0.81 | CCR3 (0.73) | CCR3GRIN2BCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7259173-B2 | Derivatives of 3-phenyl-n-(2-(4-benzyl)-piperidin-1-yl)-ethyl)-acrylamid with ccr-3-receptor antagonistic activity for use in the treatment of inflammations and allergic conditions | NOVARTIS AG (CH) | 2007-08-21 | — | — | US | disclosed |
| EP-1401814-B1 | DERIVATIVES OF 3-PHENYL-N-(2- (4-BENZYL) PIPERIDIN-1-YL)-ETHYL)-ACRYLAMID WITH CCR-3 RECEPTOR ANTAGONISTIC ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATIONS AND ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2006-09-06 | — | — | EP | disclosed |
| US-20040180926-A1 | Derivatives of 3-phenyl-n-(2-(4-benzyl)-piperidin-1-yl)-ethyl)-acrylamid with ccr-3-receptor antagonistic activity for use in the treatment of inflammations and allergic conditions | NOVARTIS AG (CH) | 2004-09-16 | — | — | US | disclosed |
| EP-1401814-A1 | DERIVATIVES OF 3-PHENYL-N-(2- (4-BENZYL) PIPERIDIN-1-YL)-ETHYL)-ACRYLAMID WITH CCR-3 RECEPTOR ANTAGONISTIC ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATIONS AND ALLERGIC CONDITIONS | Novartis AG (CH) | 2004-03-31 | — | — | EP | disclosed |
| WO-2002102775-A1 | DERIVATIVES OF 3-PHENYL-N-(2- (4-BENZYL) PIPERIDIN-1-YL)-ETHYL)-ACRYLAMID WITH CCR-3 RECEPTOR ANTAGONISTIC ACTIVITY FOR USE IN THE TREATMENT OF INFLAMMATIONS AND ALLERGIC CONDITIONS | NOVARTIS AG (CH) | 2002-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180926-A1 | Derivatives of 3-phenyl-n-(2-(4-benzyl)-piperidin-1-yl)-ethyl)-acrylamid with ccr-3-receptor antagonistic activity for use in the treatment of inflammations and allergic conditions | CCR1, CCR3, CCR4 | PRMT3 824/4885CARM1 621/4885PRMT6 2202/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.